MXPA03010679A - Una composicion para acelerar la cicatrizacion de fractura osea. - Google Patents
Una composicion para acelerar la cicatrizacion de fractura osea.Info
- Publication number
- MXPA03010679A MXPA03010679A MXPA03010679A MXPA03010679A MXPA03010679A MX PA03010679 A MXPA03010679 A MX PA03010679A MX PA03010679 A MXPA03010679 A MX PA03010679A MX PA03010679 A MXPA03010679 A MX PA03010679A MX PA03010679 A MXPA03010679 A MX PA03010679A
- Authority
- MX
- Mexico
- Prior art keywords
- bone fracture
- compositions
- patients
- promoting healing
- promoting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee una composicion para acelerar la cicatrizacion de la fractura osea, la cual comprende un inhibidor de PDE4 como un ingrediente activo, especificamente una composicion que comprende un inhibidor de PDE4 y un polimero biocompatible y biodegradable, dicha formulacion, cuando se formula dentro de una forma adecuada para administracion local tal como una preparacion de microesfera, puede proveer una composicion farmaceutica que muestra un efecto excelente en la cicatrizacion temprana de la fractura osea; dicha composicion es util en la cicatrizacion de fracturas refractorias en gente anciana y en pacientes diabeticos y con osteoporosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001154064 | 2001-05-23 | ||
PCT/JP2002/004931 WO2002094321A1 (fr) | 2001-05-23 | 2002-05-22 | Compositions favorisant la guérison d'une fracture osseuse |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03010679A true MXPA03010679A (es) | 2004-03-02 |
Family
ID=18998478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03010679A MXPA03010679A (es) | 2001-05-23 | 2002-05-22 | Una composicion para acelerar la cicatrizacion de fractura osea. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20040146561A1 (es) |
EP (1) | EP1389468A4 (es) |
JP (2) | JP4510384B2 (es) |
KR (1) | KR20040007596A (es) |
CN (1) | CN1520313A (es) |
AR (1) | AR033918A1 (es) |
CA (1) | CA2447619A1 (es) |
MX (1) | MXPA03010679A (es) |
WO (1) | WO2002094321A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI221838B (en) | 2001-08-09 | 2004-10-11 | Tanabe Seiyaku Co | Pyrazinoisoquinoline compound or naphthalene compound |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
WO2007058392A1 (ja) * | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
US8329761B2 (en) | 2006-02-13 | 2012-12-11 | Eastman Kodak Company | Oil-in-oil emulsions |
US20100034892A1 (en) | 2006-08-30 | 2010-02-11 | The Trustees Of Columbia University In The City Of New York | Treatment for bone formation disorders by growth factor delivery |
EP2030640B1 (en) * | 2007-08-27 | 2012-01-25 | Arthrex, Inc. | Capsules for delivery of bone marrow aspirate |
ES2431824T3 (es) * | 2009-01-19 | 2013-11-28 | Daiichi Sankyo Company, Limited | Compuesto cíclico que tiene heteroátomo |
US20100291027A1 (en) * | 2009-05-14 | 2010-11-18 | Jason Campbell | Hyaluronic acid (ha) injection vehicle |
EP2498798A4 (en) * | 2009-11-10 | 2014-01-01 | Univ Columbia | COMPOSITIONS AND METHODS OF WOUND TREATMENT |
US20140056960A1 (en) * | 2010-12-29 | 2014-02-27 | Imperial Innovations Limited | Methods for Improving Fracture Healing and Bone Formation |
WO2012169518A1 (ja) * | 2011-06-07 | 2012-12-13 | ホソカワミクロン株式会社 | 液状組成物及びそれを用いた化粧料並びに育毛剤 |
CN111449185A (zh) * | 2014-03-27 | 2020-07-28 | 小川香料株式会社 | 乳化组合物 |
CN110099677A (zh) * | 2016-10-28 | 2019-08-06 | 斯皮内特赫拉公司 | 药物组合物及其用途 |
KR102587602B1 (ko) | 2022-12-29 | 2023-10-13 | 황만기 | 골절 회복을 촉진하는 조성물의 제조방법 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193926A (en) | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
JPS5619324A (en) | 1979-07-24 | 1981-02-24 | Asahi Electronics | Wheel passage type anchoring clamp |
US4542025A (en) * | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
JPS6067417A (ja) | 1983-09-24 | 1985-04-17 | Tetsuo Kato | 生体内代謝性マイクロカプセルの製法 |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
GB8406906D0 (en) | 1984-03-16 | 1984-04-18 | Akzo Nv | Benzo-thiazole and benzothiophene derivatives |
DK159431C (da) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
JPH0720859B2 (ja) | 1985-02-07 | 1995-03-08 | 武田薬品工業株式会社 | マイクロカプセルの製造法 |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5939388A (en) * | 1986-07-01 | 1999-08-17 | Rosen; Vicki A. | Methods of administering BMP-5 compositions |
DE3770095D1 (de) | 1986-08-21 | 1991-06-20 | Pfizer | Chinazolindione und pyridopyrimidindione. |
JPH0725689B2 (ja) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
US5000886A (en) | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
DE3738228A1 (de) | 1987-11-11 | 1989-05-24 | Hoechst Ag | Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln |
JPH01305929A (ja) | 1988-06-02 | 1989-12-11 | Toshiba Corp | X線診断装置 |
WO1990009783A1 (en) | 1989-02-22 | 1990-09-07 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
GB8913889D0 (en) | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
JP2578001B2 (ja) | 1989-12-11 | 1997-02-05 | 明治製菓株式会社 | 抗痴呆薬 |
GB8929208D0 (en) | 1989-12-27 | 1990-02-28 | Almirall Lab | New xanthine derivatives |
DE69132329T2 (de) | 1990-04-25 | 2000-11-30 | Nissan Chemical Ind Ltd | Pyridazinonderivat |
US5288496A (en) * | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
ES2157887T3 (es) | 1990-05-30 | 2001-09-01 | Takeda Chemical Industries Ltd | Compuestos heterociclicos que contienen azufre. |
CA2043715C (en) | 1990-06-01 | 1997-01-07 | Fumio Suzuki | Imidazonaphthyridine derivatives |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
YU48420B (sh) | 1991-03-25 | 1998-07-10 | Hoechst Aktiengesellschaft | Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem |
JPH0558882A (ja) | 1991-09-04 | 1993-03-09 | Yoshiaki Kawashima | ナノカプセルの製造法 |
JP3205884B2 (ja) | 1991-10-01 | 2001-09-04 | 武田薬品工業株式会社 | 凝集防止剤をコーティングした徐放性微粒子製剤 |
PH31245A (en) | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5291490A (en) * | 1992-02-18 | 1994-03-01 | At&T Bell Laboratories | Node for a communication network |
JP3042156B2 (ja) * | 1992-02-20 | 2000-05-15 | 田辺製薬株式会社 | ナフタレン誘導体、その製法及びその合成中間体 |
AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5214008A (en) * | 1992-04-17 | 1993-05-25 | Guardian Industries Corp. | High visible, low UV and low IR transmittance green glass composition |
DE4223169C1 (de) | 1992-07-10 | 1993-11-25 | Ferring Arzneimittel Gmbh | Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe |
JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
PL307265A1 (en) * | 1992-07-28 | 1995-05-15 | Rhone Poulenc Rorer Ltd | Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom |
JP2911732B2 (ja) | 1992-10-01 | 1999-06-23 | 田辺製薬株式会社 | 徐放性多核マイクロスフェア製剤およびその製法 |
US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
JPH06305983A (ja) | 1993-04-21 | 1994-11-01 | Sangi Co Ltd | 薬剤徐放用製剤 |
US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
GB9309324D0 (en) | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
PT711282E (pt) * | 1993-07-28 | 2002-11-29 | Aventis Pharma Ltd | Compostos inibidores de pde iv e de fnt |
JPH07101861A (ja) * | 1993-08-10 | 1995-04-18 | Tanabe Seiyaku Co Ltd | 抗喘息薬 |
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
US5502072A (en) * | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
DK0730588T3 (da) * | 1993-11-26 | 1997-12-08 | Pfizer | Isoxazolinforbindelser som antiinflammatoriske midler |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
GB9412383D0 (en) | 1994-06-21 | 1994-08-10 | Celltech Ltd | Chemical compound |
GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
AU695230B2 (en) | 1994-06-24 | 1998-08-06 | Euro-Celtique S.A. | Compounds for and method of inhibiting phosphodiesterase IV |
NZ291507A (en) | 1994-08-29 | 1997-12-19 | Yamanouchi Pharma Co Ltd | 1,8-naphthyridine derivatives; medicaments |
JP3790567B2 (ja) | 1994-09-30 | 2006-06-28 | 武田薬品工業株式会社 | 徐放剤 |
US5614515A (en) * | 1994-11-17 | 1997-03-25 | University Of Southern California | Lazaroid-based compositions and method for preventing adhesion formation using the same |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
CA2214889C (en) * | 1995-03-10 | 2005-05-24 | Hans Koll | Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof |
TW332201B (en) * | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
US5910492A (en) | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
JP3033090B2 (ja) * | 1995-06-15 | 2000-04-17 | 田辺製薬株式会社 | ナフタレン誘導体、その製法及びその合成中間体 |
IL118469A (en) * | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
JPH09110678A (ja) | 1995-10-19 | 1997-04-28 | Tanabe Seiyaku Co Ltd | 被覆マイクロスフェア製剤およびその製法 |
GB9523267D0 (en) | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
JP3765338B2 (ja) | 1995-12-15 | 2006-04-12 | 武田薬品工業株式会社 | 注射用徐放性製剤の製造法 |
JP3191004B2 (ja) | 1995-12-15 | 2001-07-23 | 武田薬品工業株式会社 | マイクロスフェアの製造法 |
CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
EP0873311A1 (en) * | 1995-12-15 | 1998-10-28 | Merck Frosst Canada Inc. | Tri-aryl ethane derivatives as pde iv inhibitors |
GB9603723D0 (en) | 1996-02-22 | 1996-04-24 | Merck & Co Inc | Diphenyl pyridyl derivatives as pde iv inhibitors |
JPH09169665A (ja) * | 1995-12-21 | 1997-06-30 | Kenichi Miyamoto | 骨粗鬆症治療剤 |
GB9526325D0 (en) | 1995-12-22 | 1996-02-21 | Bp Exploration Operating | Inhibitors |
US6010711A (en) * | 1996-01-26 | 2000-01-04 | University Of Rochester | Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors |
GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
DE19617864A1 (de) | 1996-04-23 | 1997-10-30 | Schering Ag | Neue chirale Phenyldihydrofuranone |
BR9709015A (pt) | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv |
EP0912519A1 (en) * | 1996-05-20 | 1999-05-06 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
AU3724497A (en) * | 1996-07-12 | 1998-02-09 | Lava, Inc. | Digital video system having a data base of coded data for digital audio and ideo information |
CA2264798A1 (en) * | 1996-09-04 | 1998-03-12 | Pfizer Inc. | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
JP4354016B2 (ja) * | 1996-11-29 | 2009-10-28 | 株式会社メディサイエンスプラニング | 新規プリン誘導体およびこれを含む医薬組成物 |
ID19155A (id) * | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
JP3951395B2 (ja) | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
JP2001519818A (ja) | 1997-04-16 | 2001-10-23 | ホワイト、スポット、アクチェンゲゼルシャフト | 生物分解性骨接合移植片 |
FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
FR2764514B1 (fr) * | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
JP3240593B2 (ja) | 1998-02-16 | 2001-12-17 | 株式会社高研 | 可溶性コラーゲンパウダーを担体とする医薬徐放剤 |
US6451335B1 (en) * | 1998-07-02 | 2002-09-17 | Euro-Celtique S.A. | Formulations and methods for providing prolonged local anesthesia |
MY121142A (en) * | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
FR2793684B1 (fr) * | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
CA2381802C (en) * | 1999-08-21 | 2010-12-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of roflumilast and salmeterol |
EP1239856A1 (en) | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
JP3718708B2 (ja) | 2000-01-19 | 2005-11-24 | 独立行政法人物質・材料研究機構 | リン酸カルシウム系生体用セラミック焼結体およびその製造方法 |
JP2003520852A (ja) * | 2000-01-27 | 2003-07-08 | アメリカン・サイアナミド・カンパニー | α−スルホニルヒドロキサム酸誘導体を製造する方法 |
DK1252157T3 (da) * | 2000-01-31 | 2004-10-25 | Pfizer Prod Inc | Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
EP1277465A1 (en) | 2000-04-24 | 2003-01-22 | Tanabe Seiyaku Co., Ltd. | Process for producing microsphere |
EP1277787A4 (en) | 2000-04-28 | 2009-11-11 | Mitsubishi Tanabe Pharma Corp | PROCESS FOR PREPARING A MICROSPHERE |
ATE332708T1 (de) * | 2000-06-06 | 2006-08-15 | Glaxo Group Ltd | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält |
BR0113167A (pt) * | 2000-08-11 | 2003-06-24 | Ono Pharmaceutical Co | Derivados de piperidina e agente que compreende o derivado como ingrediente ativo |
DE10061137B4 (de) * | 2000-12-07 | 2016-10-06 | Takeda Gmbh | Neue pharmazeutische Zubereitung |
IL156413A0 (en) * | 2001-01-31 | 2004-01-04 | Pfizer Prod Inc | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
EE200300362A (et) * | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid |
JP4364179B2 (ja) | 2005-08-15 | 2009-11-11 | 株式会社ソニー・コンピュータエンタテインメント | 描画処理装置および描画処理方法 |
-
2002
- 2002-05-22 JP JP2002591037A patent/JP4510384B2/ja not_active Expired - Fee Related
- 2002-05-22 KR KR10-2003-7015231A patent/KR20040007596A/ko not_active Application Discontinuation
- 2002-05-22 MX MXPA03010679A patent/MXPA03010679A/es not_active Application Discontinuation
- 2002-05-22 EP EP02771772A patent/EP1389468A4/en not_active Withdrawn
- 2002-05-22 US US10/478,709 patent/US20040146561A1/en not_active Abandoned
- 2002-05-22 CA CA002447619A patent/CA2447619A1/en not_active Abandoned
- 2002-05-22 WO PCT/JP2002/004931 patent/WO2002094321A1/ja active Application Filing
- 2002-05-22 CN CNA028127331A patent/CN1520313A/zh active Pending
- 2002-05-23 AR ARP020101912A patent/AR033918A1/es not_active Application Discontinuation
-
2007
- 2007-07-19 US US11/826,921 patent/US7659273B2/en not_active Expired - Fee Related
-
2010
- 2010-02-17 JP JP2010032734A patent/JP2010155849A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4510384B2 (ja) | 2010-07-21 |
US7659273B2 (en) | 2010-02-09 |
EP1389468A1 (en) | 2004-02-18 |
JP2010155849A (ja) | 2010-07-15 |
EP1389468A4 (en) | 2007-01-10 |
KR20040007596A (ko) | 2004-01-24 |
US20080031958A1 (en) | 2008-02-07 |
AR033918A1 (es) | 2004-01-07 |
CN1520313A (zh) | 2004-08-11 |
WO2002094321A1 (fr) | 2002-11-28 |
US20040146561A1 (en) | 2004-07-29 |
CA2447619A1 (en) | 2002-11-28 |
JPWO2002094321A1 (ja) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
MXPA03010679A (es) | Una composicion para acelerar la cicatrizacion de fractura osea. | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
CA2454584A1 (en) | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient | |
BR9406893A (pt) | Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids | |
HUP0402389A2 (hu) | Ritmusszabályozó hatóanyagokat tartalmazó gyógyszerkészítmények és alkalmazásuk medencetáji fájdalmak kezelésére | |
WO2003099992A3 (en) | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins | |
DE69501419T2 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol | |
UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
PL323364A1 (en) | Bicyclic aromatic compounds | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
HUP0400553A2 (hu) | Gyógyászati készítmények | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
MXPA03010672A (es) | Composicion para el tratamiento regenerativo de enfermedades del cartilago. | |
BRPI0407178A (pt) | Composição farmacêutica osteogênica | |
WO2000001415A3 (en) | Use of inhibitors of protein kinase c epsilon to treat pain | |
CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
SE0102887D0 (sv) | New formulation | |
WO2003043632A3 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
BR0104586A (pt) | Método para tratamento de neurodegeneração | |
AR012702A1 (es) | Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente | |
HUP0204258A3 (en) | Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |